Amendment to 3,4-MDP-2-P Methyl Glycidic Acid, a List I Chemical
DEA proposes to expand List I chemical 3,4-MDP-2-P methyl glycidic acid (PMK glycidic acid) to include its esters, affecting chemical handlers and pharmaceutical supply chains.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on August 1, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Chemical manufacturers, distributors, importers, and exporters handling PMK glycidic acid or its esters; also downstream pharmaceutical companies and pharmacies that may encounter these chemicals. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified in the excerpt; check the Federal Register document for comment period and effective date.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The DEA is proposing to modify the listing of the List I chemical 3,4-MDP-2-P methyl glycidic acid to include its esters, which would subject these esters to the same regulatory controls as the parent chemical.
Who it affects
Chemical manufacturers, distributors, importers, and exporters handling PMK glycidic acid or its esters; also downstream pharmaceutical companies and pharmacies that may encounter these chemicals.
What you must do
Review current handling and reporting procedures for PMK glycidic acid and its esters; prepare to comply with expanded List I chemical regulations once finalized.
Deadline
Not specified in the excerpt; check the Federal Register document for comment period and effective date.
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- US-CONGRESS HR1266: Combating Illicit Xylazine Act
- Louisiana v. FDA: Access to Mifepristone Back at the Supreme Court - kff.org
- Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs; Guidance for Industry; Availability
- Prisma Health Midlands to Pay $1 Million to Resolve Alleged Controlled Substance Act Violations - DEA.gov
- Utah opens applications for another medical cannabis license - mjbizdaily.com